Proactive Investors - Run By Investors For Investors

CytoDyn requests FDA meeting to discuss clearance of prostate cancer-detection test

The ProstaGene Prognostic Test is intended for use in patients who have undergone a prostate biopsy and been found to have prostate cancer
prostate cancer
Prostate cancer is the second most common diagnosed cancer among men, behind skin cancer

CytoDyn Inc (OTCMKTS:CYDY) announced Wednesday it has requested a meeting with the US Food and Drug Administration to discuss the 510(k) application for FDA clearance of its ProstaGene Prognostic Test. 

The test is intended for use in patients who have undergone a prostate biopsy and been found to have prostate cancer by the Gleason score, which is a classification system to help determine treatment and predict the outlook for prostate cancer -- the second most common diagnosed cancer among men, behind skin cancer.

To support its application for FDA clearance, CytoDyn said it will cite a previously published retrospective clinical study in two populations of men (79 and 139 men), a subsequent study in 130 men and a recent study of 218 men. 

READ; Breakthrough test predicts which HIV patients will respond to CytoDyn's leronlimab as a monotherapy

The Vancouver, Washington-based biotech said the test was developed by Dr Richard Pestell, the company's chief medical officer. The test became an asset of CytoDyn upon its acquisition in November 2018 of ProstaGene, a biotech company founded by Dr Pestell.

The test, which uses a gene signature and computer algorithm to create a score, could revolutionize the detection and treatment of prostate cancer at less cost while helping to maintain a patient’s quality of life.

Aggressive treatments' long-term side effects

Aggressive treatment has significant long-term side effects like incontinence, erectile dysfunction, and urinary dribbling.

“The inability to determine which cases of prostate cancer may be aggressive leads to significant and, often, unnecessary highly invasive treatment,” Dr Pestell said. “The development of an FDA-cleared prostate cancer prognostic test may aid patients and physicians in better decision-making.”

CytoDyn’s stock recently traded flat at $0.52 on the OTC Market.  

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full CYDY profile View Profile

CytoDyn Timeline

Related Articles

A double helix and a medical person
March 07 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Enzymes under a microscope
April 29 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use